Athersys, Inc. (ATHXQ)

Market Cap	6.18K -97.7%
Revenue (ttm)	80.00K -98.7%
Net Income	-37.51M
EPS	-1.89
Shares Out	61.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,426
Average Volume	13,449
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	n/a
Beta	56.20
RSI	66.00
Earnings Date	n/a

About Athersys

Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition of Athersys, Inc. for reorganization under Chapter 11 was converted to...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 24
• Stock Exchange: OTCMKTS
• Ticker Symbol: ATHXQ

Financial Performance

In 2022, Athersys's revenue was $5.33 million, a decrease of -3.43% compared to the previous year's $5.51 million. Losses were -$72.53 million, -16.58% less than in 2021.